Illuminating the molecular basis for some antipsychotic drug-induced metabolic burden.
Meltzer
Herbert Y
HY
Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, TN 37212, USA.
D000091162:AMP-Activated Protein Kinase Kinases; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000378:metabolism* / Q000494:pharmacology / Q000627:therapeutic use; D001569:Benzodiazepines; D003987:Dibenzothiazepines; D006801:Humans; D007031:Hypothalamus / Q000187:drug effects*; D000077152:Olanzapine; D011494:Protein Kinases / Q000378:metabolism*; D000069348:Quetiapine Fumarate; D018967:Risperidone; D012559:Schizophrenia / Q000188:drug therapy*; D015430:Weight Gain
D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D001569:Benzodiazepines; D000069348:Quetiapine Fumarate; D011494:Protein Kinases; D000091162:AMP-Activated Protein Kinase Kinases; D018967:Risperidone; D000077152:Olanzapine